Evidence map›Paper›PMID 41082386›Full record

ArticleCancer science2025

Integration of scRNA-Seq and scATAC-Seq Reveals Malignant Characteristics of Sarcomatoid Clear Cell Renal Cell Carcinoma.

Wenhao Lu, Yixuan Liu, Jizhen Cen, Shengzhu Huang, Zheng Wen, Jiaping Li, Zengnan Mo, Xuefang Liang, Zheng Lu, Cheng Su and 1 more

Abstract read
In one paragraph

Article in Cancer science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Wenhao LuDepartment of Urology, The First Affiliated Hospital of Guangxi Medical University, Guangxi Medical University, Nanning, Guangxi, China.
Yixuan LiuDepartment of Urology, The First Affiliated Hospital of Guangxi Medical University, Guangxi Medical University, Nanning, Guangxi, China.
Jizhen CenCenter for Genomic and Personalized Medicine, Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, Guangxi, China.
Shengzhu HuangCenter for Genomic and Personalized Medicine, Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, Guangxi, China.
Zheng WenCenter for Genomic and Personalized Medicine, Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, Guangxi, China.
Jiaping LiGuangxi Key Laboratory of Precision Medicine in Cardio-Cerebrovascular Diseases Control and Prevention, First Affiliated Hospital of Guangxi Medical University, Guangxi Medical University, Nanning, Guangxi, China.
Zengnan MoDepartment of Urology, The First Affiliated Hospital of Guangxi Medical University, Guangxi Medical University, Nanning, Guangxi, China.
Xuefang LiangCenter for Genomic and Personalized Medicine, Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, Guangxi, China.
Zheng LuDepartment of Urology, The First Affiliated Hospital of Guangxi Medical University, Guangxi Medical University, Nanning, Guangxi, China.
Cheng SuCenter for Genomic and Personalized Medicine, Guangxi Key Laboratory for Genomic and Personalized Medicine, Guangxi Collaborative Innovation Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, Guangxi, China.
Zhenyuan YuDepartment of Urology, The First Affiliated Hospital of Guangxi Medical University, Guangxi Medical University, Nanning, Guangxi, China.ORCID https://orcid.org/0000-0002-3848-5504

Funding

China Postdoctoral Science Foundation 2024MD763944Natural Science Foundation of Guangxi Zhuang Autonomous Region 2018GXNSFAA138192Natural Science Foundation of Guangxi Zhuang Autonomous Region 2024GXNSFBA010055Natural Science Foundation of Guangxi Zhuang Autonomous Region 2025GXNSFAA069407Youth Science Foundation of Guangxi Medical University GXMUYSF202403Youth Science Foundation of Guangxi Medical University GXMUYSF202409
6 · The paper itself

Abstract

Clear cell renal cell carcinoma (ccRCC) with sarcomatoid differentiation is a rare histological type of ccRCC, characterized by aggressive clinical behavior and poor prognosis. However, the malignant characteristics of this disease have yet to be fully elucidated. Here, we performed single-cell RNA sequencing (scRNA-seq), single-cell assay for transposase-accessible chromatin using sequencing (scATAC-seq), and WES analysis on a single patient with sarcomatoid ccRCC. By integrating scRNA-seq and scATAC-seq data from 19 previous classical ccRCC samples (19,819 tumor cells and 21,684 nuclei), we firstly identified the transcriptional regulatory features of sarcomatoid differentiated tumor cells by scATAC-seq, primarily evidenced by active binding with FOS/JUND, FOSL1/JUN, and FOSL2. In addition, we identified DST, FRMD4A, and PREX2 as tumor markers for ccRCC with sarcomatoid differentiation, which were validated in a cohort study. Moreover, we determined that PREX2 played a malignant role in ccRCC with sarcomatoid differentiation in vitro and in vivo, facilitating tumor progression by inhibiting PTEN and activating the PI3K/AKT pathway. This study demonstrated the comprehensive gene expression and DNA regulation information of ccRCC with sarcomatoid differentiation, highlighting its malignant characteristics, thereby offering novel insights for the diagnosis and treatment of sarcomatoid ccRCC.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsSingle-Cell AnalysisAnimalsBiomarkers, TumorCell DifferentiationCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansMaleMicePTEN PhosphohydrolaseRNA-SeqSequence Analysis, RNASingle-Cell Gene Expression AnalysisBiomarkers, TumorPTEN PhosphohydrolasePTEN protein, humanclear cell renal cell carcinomamalignant characteristicssarcomatoid differentiationscATAC‐seqscRNA‐seq

Identifiers

PMID41082386
PMCPMC12666471

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.